The incidence of phenylketonuria (PKU) in Finland is extremely low, probably below 1 in 100 000. We describe the mutations and haplotypes in all four presently known patients. Mutation R408W was found on four mutant chromosomes (all haplotype 2), and IVS7ntl, R261Q, and IVS2ntl were each found on a single chromosome. No mutation was found on the remaining chromosome. These findings support a pronounced negative founder effect as the cause of the low incidence of PKU in Finland, and are consistent with existing data regarding the European and Baltic origin of Finnish genes. (J Med Genet 1995;32:976-978) 
Studies are being conducted to determine the origin and spread of the different mutations of the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU) . Of particular interest is the prevalent R408W mutation. Based on haplotype data, this mutation is now believed to have arisen at least twice, once in western Europe (on haplotype 1) and once in eastern Europe (on haplotype 2). 2 Finland is located at the northern border between east and west in Europe so the distribution of mutations and haplotypes might be expected to have both eastern and western characteristics. Yet no molecular data on PAH mutations have so far been published. This is because of the extremely low incidence of PKU in Finland. The first patient diagnosed in Finland was found by screening 509 institutionalised people with severe mental retardation.3 Further attempts to screen for PKU in Finland were reported by Palo4 who found two patients among a total of 2090 mentally retarded subjects. Visakorpi et a15 screened a further 1595 mentally retarded people without finding any PKU patients. These data suggested a prevalence of 0-54 per 1000 among the severely mentally retarded, a figure less than one-tenth of the corresponding figures in northern European countries studied by similar methods. 6 To settle the question of the incidence of PKU in Finland, Visakorpi et '6 and no data indicating its origin have been reported. The IVS2ntl mutation has been found only in Palestinian Arabs, where it is linked to RFLP haplotypes 7 and 42.1' Its detection on one chromosome in Finland might seem surprising; however, it is carried by the patient's father who is a recent Palestinian immigrant. We note with interest that this mutation exceptionally occurs on haplotype 11.
How do these findings relate to the extremely low frequency of PKU in Finland and to the origins of the Finnish population? The predominance of R408W (on four of eight mutant alleles) is fully consistent with the fact that this mutation is common in all of Finland's neighbours, for example, Sweden to the west (22%), Lithuania to the south (69%), and St Petersburg to the east (67%).' The fact-that all four R408W mutations occur on haplotype 2 is again consistent with the corresponding proportions in Sweden (92%), Lithuania (100%), and St Petersburg (100%). These findings, together with the occurrence of other single mutations whose origins are scattered, is consistent with the present day Finnish gene pool being of a general European nature with a strong "Baltic" component.
"
The extremely low incidence of PKU mutations in Finland is best explained by a combination of founder effect, population bottlenecks, and genetic drift, that is, by chance. That a negative founder effect could alone account for the low incidence is illustrated by the fact that Finland's present population of 5 population: molecular characterisation of Phenylketonuria in a low incidence
